Financial reports
10-K
2023 FY
Annual report
21 Mar 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
10-Q
2023 Q2
Quarterly report
7 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
10-K
2022 FY
Annual report
29 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
10 Aug 22
10-Q
2022 Q1
Quarterly report
12 May 22
10-K
2021 FY
Annual report
30 Mar 22
Current reports
8-K
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
21 Mar 24
8-K
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Bolt Biotherapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
7 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
13 Jun 23
8-K
Bolt Biotherapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
11 May 23
8-K
Bolt Biotherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
29 Mar 23
8-K
Departure of Directors or Certain Officers
14 Dec 22
8-K
Bolt Biotherapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
10 Nov 22
8-K
Bolt Biotherapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
10 Aug 22
8-K
Submission of Matters to a Vote of Security Holders
10 Jun 22
Registration and prospectus
S-8
Registration of securities for employees
21 Mar 24
S-8
Registration of securities for employees
29 Mar 23
424B5
Prospectus supplement for primary offering
7 Apr 22
S-3
Shelf registration
30 Mar 22
S-8
Registration of securities for employees
30 Mar 22
D
$15M in equity, sold $15M, 1 investor
7 Jun 21
S-8
Registration of securities for employees
5 Feb 21
424B4
Prospectus supplement with pricing info
5 Feb 21
S-1MEF
Registration of additional securities for an S-1
4 Feb 21
S-1/A
IPO registration (amended)
3 Feb 21
Other
EFFECT
Notice of effectiveness
8 Apr 22
UPLOAD
Letter from SEC
6 Apr 22
CORRESP
Correspondence with SEC
5 Apr 22
EFFECT
Notice of effectiveness
5 Feb 21
CERT
Certification of approval for exchange listing
4 Feb 21
SEC STAFF
SEC staff action: Order
3 Feb 21
CORRESP
Correspondence with SEC
2 Feb 21
CORRESP
Correspondence with SEC
2 Feb 21
CORRESP
Correspondence with SEC
25 Jan 21
UPLOAD
Letter from SEC
17 Sep 20
Ownership
4
Grant Yonehiro
6 Mar 24
4
Edith A. Perez
6 Mar 24
4
Randall C Schatzman
6 Mar 24
4
William P. Quinn
6 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 24
SC 13G/A
Vivo Capital VIII, LLC
13 Feb 24
SC 13D/A
Pivotal bioVenture Partners Fund I, L.P.
12 Feb 24
5
Grant Yonehiro
6 Feb 24
5
Edith A. Perez
6 Feb 24